Today: 19 November 2025
Subscribe
Browse Category

Biotech News 18 October 2025 - 26 October 2025

Novartis’ $12B Biotech Buyout Shakes Up Avidity Biosciences (RNA) – Is the Rare-Disease Stock Set to Soar?

Novartis’ $12B Biotech Buyout Shakes Up Avidity Biosciences (RNA) – Is the Rare-Disease Stock Set to Soar?

Bottom Line: Avidity Biosciences’ stock is set to explode higher on Novartis’s $12 billion buyout, capping off a dramatic run fueled by breakthrough science and takeover buzz. The high-premium deal underscores the massive value of RNA therapeutics for rare diseases – and signals that big pharma’s biotech spending spree isn’t slowing down. While Avidity’s chapter as an independent company is closing, its novel treatments may reach patients faster under Novartis’s umbrella. Investors now await the finalization of the deal (and SpinCo details), as Wall Street cheers another biotech success story in the making. 🏥💥 Sources: reuters.com reuters.com business-standard.com biospace.com biospace.com
26 October 2025
 ·  ·  ·  · 
Theriva Biologics (TOVX) Stock Soars 92% on Oncolytic Virus Trial News – Can the Rally Last?

Theriva Biologics (TOVX) Stock Surges on Cancer Trial Breakthrough – What’s Next?

Theriva’s Stock Swing: In mid-October, Theriva’s Nasdaq-traded shares spiked on news of clinical success. On Oct. 15 the stock jumped from roughly $0.44 to $0.84 intraday ts2.tech, an increase of about 92%. This surge coincided with reports that VCN-01 had met the primary endpoints in the VIRAGE Phase 2b trial (see below). The very next trading day, Theriva disclosed a $4.0 million warrant inducement financing. Investors exercising warrants at $0.54 per share provided immediate cash ts2.tech, but the announcement also trimmed the earlier stock rally – TOVX settled in the mid-$0.40 range by Oct. 16 ts2.tech ts2.tech. In the days
24 October 2025
 ·  ·  ·  ·  · 
Neuphoria Stock Crashes After Social Anxiety Trial Failure — What’s Next?

Neuphoria Stock Crashes After Social Anxiety Trial Failure — What’s Next?

Key Facts: – Neuphoria (Nasdaq: NEUP) shares plunged ~67% in after-hours trading on Oct 20 when its lead drug BNC210 failed a Phase 3 SAD trial investing.com. The AFFIRM-1 trial missed both primary and secondary endpoints, and the company immediately halted its social anxiety program and launched a full strategic review investing.com globenewswire.com. – CEO Spyros Papapetropoulos vowed to “conserve our cash position” while exploring options to “maximize value for shareholders” globenewswire.com. Neuphoria will evaluate BNC210 in PTSD (where earlier data were promising) and otherwise cut spending. – NEUP stock fell from about $15.40 on Oct 20 to roughly $5
24 October 2025
 ·  ·  ·  ·  · 
Armata (ARMP) Stock Surges 150% After Breakthrough Bacteriophage Trial Results

Armata (ARMP) Stock Surges 150% After Breakthrough Bacteriophage Trial Results

Armata’s stock performance this week has been nothing short of dramatic. Prior to Oct. 22, ARMP had been trading in the low-$3 range (for example, it closed around $3.41 on Oct. 16 marketbeat.com). Once the late-breaking IDWeek data was announced, the shares rocketed – briefly hitting an intraday high near $16 (per some quotes) before settling at about $8.87 finviz.com investing.com. For context, that $8.87 close is the stock’s highest level in years (FinViz shows a 52-week high of only $3.50 prior to today). By midday on Oct. 22, Investing.com already noted the stock was up ~95% on the day
22 October 2025
 ·  ·  ·  · 
Thermo Fisher Stock Skyrockets – Biotech Boom & Big Deals Fuel Rally, Analysts Eye $650

Thermo Fisher Stock Skyrockets – Biotech Boom & Big Deals Fuel Rally, Analysts Eye $650

Stock Performance and Sector Rally Thermo Fisher’s stock price has surged in recent weeks on renewed investor optimism. After a slow start to 2025 (even a ~10% year-over-year dip early in the year), the stock turned higher in October. TS2.Tech notes the stock “rallied strongly in recent weeks – up over 11% in October after a slower start to the year” ts2.tech. On Oct. 1, Thermo Fisher jumped about +9.8% as healthcare stocks rallied following a U.S. drug-pricing deal markets.financialcontent.com. The sector’s strength continued into early October: Biogen climbed +10.9% and Thermo +9.4% on Oct. 1 ts2.tech, and TMO again
22 October 2025
 ·  ·  ·  ·  · 
Minerva Neurosciences Stock Skyrockets on $200M Lifeline for Schizophrenia Drug

Minerva Neurosciences Stock Skyrockets on $200M Lifeline for Schizophrenia Drug

Stock Soars on Major Funding News Minerva Neurosciences’ stock chart went vertical on Tuesday after the biotech announced an expansive financing deal that effectively triples the company’s market capitalization overnight marketbeat.com. In pre-market trading on Oct. 21, NERV stock jumped as much as 160% on the news gurufocus.com. The shares opened around $6–7 (up from ~$2.66 prior close) and oscillated near those levels through the day, ultimately marking a 52-week high of $6.97 marketbeat.com. By comparison, NERV had traded as low as $1.15 within the past year marketbeat.com, reflecting both the dramatic rebound and the extreme volatility inherent in this
21 October 2025
 ·  ·  ·  · 
iBio Stock Surges on Bullish Analyst Calls and Obesity Drug Breakthroughs

iBio Stock Surges on Bullish Analyst Calls and Obesity Drug Breakthroughs

IBIO Stock Price and Recent Volatility As of midday October 21, 2025, iBio’s stock (NASDAQ: IBIO) trades around $0.89 per share marketbeat.com. The price has been volatile in recent days. Last week, shares jumped over 20% in pre-market trading on October 17 after Leerink Partners issued a bullish initiation, although the stock later settled near $0.85 by that day’s close marketbeat.com. Even with these upticks, iBio’s stock remains well below its levels earlier this year – it began 2025 at ~$2.45 and has declined about 63% year-to-date marketbeat.com. This underperformance comes amid broader small-cap biotech volatility; by comparison, the biotech
21 October 2025
 ·  ·  ·  · 
Summit Therapeutics (SMMT) Skyrockets on Cancer Breakthrough – Key Facts & Outlook

Summit Therapeutics (SMMT) Skyrockets on Cancer Breakthrough – Key Facts & Outlook

SMMT Stock’s Wild Ride in 2025 Summit Therapeutics’ share price has been on a roller-coaster ride this year. After a steady climb through late summer, SMMT spiked above $25 intraday in mid-October, then pulled back to end last week just under $21 ts2.tech. The stock fell 4.5% on Friday, Oct. 17 alone ts2.tech as traders braced for the upcoming data presentation and earnings call. Even after that dip, Summit shares remain up solidly in 2025 (low double-digit percent gains) – roughly in line with the broader biotech sector (the SPDR S&P Biotech ETF is ~+20% YTD) ts2.tech. These dramatic swings
20 October 2025
 ·  ·  ·  ·  · 
Summit Therapeutics (SMMT) Stock Soars on Cancer Breakthrough – Can the Biotech’s Rally Hold?

Summit Therapeutics (SMMT) Stock Soars on Cancer Breakthrough – Can the Biotech’s Rally Hold?

What to Know Before Markets Open on October 20, 2025 SMMT’s Wild Stock Ride in 2025 Summit Therapeutics’ share price has experienced extreme swings this year. After a steady climb through late summer, SMMT spiked to an intraday high above $25 on Oct. 13, 2025, before pulling back to end the week just under $21 stockanalysis.com. The stock fell 4.5% on Friday (Oct. 17) alone stockanalysis.com, capping a choppy few days as traders braced for the ESMO conference and earnings. Despite the recent dip, Summit’s stock is still up double-digits in 2025, roughly in line with the broader biotech sector
19 October 2025
 ·  ·  ·  ·  · 
Psychedelic Biotech Rally: Atai Life Sciences Stock Soars 18% on FDA Breakthrough and $130M Fundraise

Psychedelic Biotech Rally: Atai Life Sciences Stock Soars 18% on FDA Breakthrough and $130M Fundraise

Stock Surge & Analyst Reaction Atai shares exploded higher on Oct. 17, 2025. Investors bid the stock up ~17.7%, closing at roughly $6.45 ts2.tech (versus ~$5.48 offering price). In after-hours trading it briefly touched ~$6.86 ts2.tech. This rally follows a week of good news: BPL-003’s FDA breakthrough, plus well-received capital raise plans. Volume on Oct. 17 was very high (tens of millions of shares), reflecting heavy trading. Over 2025 the stock has skyrocketed ~348% ts2.tech, making ATAI one of the year’s top biotech performers. Its market cap now hovers around $1.2 billion ts2.tech. Analysts have taken notice. Needham Research just initiated
18 October 2025
 ·  ·  ·  ·  · 
MindMed Stock Rockets on Breakthrough LSD Anxiety Data – Analysts Eye 100% Upside

MindMed Stock Rockets on Breakthrough LSD Anxiety Data – Analysts Eye 100% Upside

Stock Soars on Catalyst News MindMed’s stock has skyrocketed in recent weeks. After languishing in the single digits, MNMD climbed above $12 in late September and spiked to $13.09 on Oct. 14, its highest level in over a year ts2.tech marketbeat.com. The surge has pushed the stock roughly +68% year-to-date ts2.tech. Heavy trading volume accompanied the rise, as investors reacted to the latest clinical and regulatory news. (By Oct 17, shares were trading around $13.60 stockinvest.us.) This rally has made MindMed one of the year’s best-performing small-cap biotechs. Wall Street sentiment is strongly positive: MarketBeat notes MNMD has seven analyst
18 October 2025
 ·  ·  ·  ·  · 
BlackRock’s Big Bet Sends SELLAS Life Sciences (SLS) Stock Soaring – What’s Next for This Biotech?

BlackRock’s Big Bet Sends SELLAS Life Sciences (SLS) Stock Soaring – What’s Next for This Biotech?

Key Facts – October 18, 2025 Stock Performance: SLS on a Tear in 2025 SELLAS Life Sciences’ stock has been on a remarkable run this year. Shares have effectively doubled in 2025, and the momentum accelerated in mid-October. On Friday Oct. 17, SLS closed at $2.14, up roughly 100% year-to-date finbold.com. In fact, during that day’s session the stock touched a 52-week high of $2.27 (more than 3× its 52-week low of $0.77) marketbeat.com. Trading activity exploded as well – volume spiked to several times the usual level (over 6.7 million shares vs ~2.2M average) amid a flurry of speculative
18 October 2025
 ·  ·  ·  ·  · 
1 2 3 4 5 … 7
Go toTop